Breast Cancer Clinical Trial
Official title:
Case Control Study to Evaluate the Impact of Radiotherapy on Patients Undergoing DIEP Flap Breast Reconstruction
The investigators intend to undertake a study to investigate the effect of radiotherapy on
deep inferior epigastric perforator flap reconstructions (DIEP). Adjuvant post-mastectomy
radiotherapy (PMRT) is offered to women at high risk of chest wall recurrence. The perceived
detrimental effect of radiotherapy on an immediate breast reconstruction and the "one-off"
nature of autologous reconstruction leads some surgeons to recommend delayed reconstruction
after mastectomy or to use a temporising implant with a view to planned exchange to
autologous reconstruction after radiotherapy. However, there remains significant uncertainty
in the literature about the impact of radiotherapy on autologous reconstructions. This study
is a mixed methology study using patient reported outcome measures (PROMS), applanation
tonometry (measure of breast compressibility), semi-structured interviews and 3 dimensional
photography analysis to compare the aesthetic and impact on quality of life on the following
groups of patients:
Patient groups:
1. Unilateral skin sparing mastectomy (SSM) with immediate DIEP flap reconstruction and
PMRT (cases)
2. Unilateral SSM with immediate DIEP flap reconstruction and no PMRT (controls)
3. Unilateral simple mastectomy, PMRT, and subsequent delayed DIEP flap reconstruction
(controls)
4. Unilateral SSM with temporizing implant, PMRT and subsequent conversion to DIEP
(controls)
| Status | Recruiting |
| Enrollment | 300 |
| Est. completion date | January 14, 2018 |
| Est. primary completion date | January 14, 2018 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: 1. Women who have undergone one of the treatment sequences above (a) - (d) Patient groups: 1. Unilateral skin sparing mastectomy (SSM) with immediate DIEP flap reconstruction and PMRT (cases) 2. Unilateral SSM with immediate DIEP flap reconstruction and no PMRT (controls) 3. Unilateral simple mastectomy, PMRT, and subsequent delayed DIEP flap reconstruction (controls) 4. Unilateral SSM with temporizing implant, PMRT and subsequent conversion to DIEP (controls) 2. Patients of any age will be included 3. Patients who are between one and five years post initial breast reconstruction surgery or radiotherapy (which ever is most recent) Exclusion Criteria: 1. Women who have undergone bilateral mastectomy, even if the contralateral mastectomy was asynchronous. 2. Women who are less than one year from their last radiotherapy treatment or from their DIEP flap reconstruction. 3. Patients who have had more than one implant based operation before DIEP flap (revision surgery to the implant implies that an implant based reconstruction was the primary intent and therefore the DIEP flap is a 'salvage' procedure) or if it is documented to be a salvage reconstruction. 4. Women who have developed recurrent / distant disease. 5. Women who are unable to stand for the 3D imaging (approximately 10 minutes) 6. Women who are unable to complete the English language questionnaire or interview (i.e. learning difficulties or patients who do not have adequate English language skills). |
| Country | Name | City | State |
|---|---|---|---|
| United Kingdom | The Royal Marsden NHS Foundation Trust | London |
| Lead Sponsor | Collaborator |
|---|---|
| Royal Marsden NHS Foundation Trust |
United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The difference in patient satisfaction score between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)) using "satisfaction with reconstructed breast" question of the BREAST-Q. | The difference in (mean or median) patient satisfaction score (ranging from 0-100) between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)) using the "satisfaction with reconstructed breast" subscale of the postoperative reconstruction module of the BREAST-Q questionnaire. | Day 1 | |
| Secondary | The difference in scores in other subscales from the BREAST-Q questionnaire between patients with an irradiated DIEP flap (group (a)) and patients with a DIEP flap who have not undergone PMRT (group (b)). | Day 1 | ||
| Secondary | The difference in patient satisfaction and all subscales between patients with an irradiated DIEP flap (group (a)) and patients who underwent PMRT prior to DIEP flap (group (c) and group (d)) using BREAST-Q scores as above. | Day 1 | ||
| Secondary | Volume and symmetry assessment of the reconstructed breast using 3D surface imaging This would consist of comparing volume and symmetry assessment between groups (a) and (b), groups (a) and (c), and groups (a) and (d). | Day 1 | ||
| Secondary | Panel assessment by independent panel of the reconstruction using 3D surface imaging. | The panel will consist of four members, a plastic surgeon, a breast surgeon, a clinical oncologist and a breast care nurse. The panel will score independently. The scoring will be between 1 and 4 | Day 1 | |
| Secondary | Applanation tonometry for assessment of the consistency of the reconstructed breast. This will consist of comparing breast compressibility in the reconstructed breast between groups (a) and (b), groups (a) and (c), and groups (a) and (d). | Day 1 | ||
| Secondary | The prevalence of fat necrosis. | The presence of fat necrosis would be either: Presence of fat necrosis (as documented by imaging) - Yes or no Surgical procedure (excluding biopsy) to treat fat necrosis - Yes or no This would consist of comparing prevalence of fat necrosis and surgical procedures required. Rates of each would be compared between groups (a) and (b), groups (a) and (c), and groups (a) and (d). |
Day 1 | |
| Secondary | The number of operative episodes for the index breast and the contralateral breast. | One visit to theatre counts as one operative episode (i.e. if multiple procedures to the same breast on one occasion then this is still just one operative episode). This would consist of comparing number of episodes in the index breast and the contra lateral breast between groups (a) and (b), groups (a) and (c), and groups (a) and (d). |
Day 1 | |
| Secondary | Analysis of time from diagnosis to definitive breast reconstruction or last radiotherapy session This would consist of a comparison of number of months treatment between group (a) and group (c), group (a) and group (d). | Day1 | ||
| Secondary | Knowledge of patient experience from interviews regarding patient satisfaction. Please refer to methodology for further details. | Day 1 | ||
| Secondary | Basic health economics of the four treatment groups. This will include cost of each operation/inpatient episodes for all breast related operations and cost of all plastic surgical outpatient events. | Day 1 | ||
| Secondary | Median length of time between end of treatment to time of the study for each of the groups a to d. | Day 1 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |